Who was studied, and how
Two numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 9 other studies
27,564people with cardiovascular disease, in this paper
Among T1DM, the trial randomly assignedassigned by chance
evolocumab
placebo
No clear effect on cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization−34%
randomisedthe abstract, start to end
… CI 0.79-0.96), 0.84 (0.75-0.93), and 0.66 (0.32-1.38) in the no diabetes, T2DM, and T1DM groups, and absolute risk reduction was 1.3%, 2.5%, and 7.3%, respectively.
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularizationevolocumab vs placebo, in T1DM
HR 0.660.32–1.38
Cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularizationevolocumab vs placebo, in T1DM
−7.30
PCSK9 inhibitorsCardiovascular events
PCSK9 inhibitors × cardiovascular eventshelps?settled
unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
1 / 7